ArticleRespiratory research2013
Interferon-inducible chemokines reflect severity and progression in sarcoidosis.
Article in Respiratory research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 84 citations in OpenAlex.
- Inhibition of type 1 immunity with tofacitinib is associated with marked improvement in longstanding sarcoidosis.Nature communications · 2022Trial
- Article
- Article
- Interferon Upregulation Associates with Insulin Resistance in Humans.Current diabetes reviews · 2025Review
- Inflammatory plasma protein levels are elevated years before sarcoidosis diagnosis: a nested case-control study in Sweden.The European respiratory journal · 2024Article
- Increased serum interferon activity in sarcoidosis compared to that in tuberculosis: Implication for diagnosis?Heliyon · 2024Article
- Sarcoidosis and Cancer: The Role of the Granulomatous Reaction as a Double-Edged Sword.Journal of clinical medicine · 2024Article
- Increased proportions of circulating PD-1Respiratory research · 2024Article
- Sarcoidosis-associated pulmonary fibrosis: joining the dots.European respiratory review : an official journal of the European Respiratory Society · 2023Review
- Calcium, Phosphate, and Vitamin D Status in Patients with Sarcoidosis-Associations with Disease Activity and Symptoms.Journal of clinical medicine · 2023Article
- Macrophage Biology in Human Granulomatous Skin Inflammation.International journal of molecular sciences · 2023Review
- Expression of IDO1 and PD-L2 in Patients with Benign Lymphadenopathies and Association with Autoimmune Diseases.Biomolecules · 2023Article
- FOXP3+ regulatory T cells are associated with the severity and prognosis of sarcoidosis.Frontiers in immunology · 2023Article
- Rationale and design of the SARCoidosis Outcomes in all respiratory Viral Infectious Diseases (SARCOVID) Study.BMJ open respiratory research · 2022Observational
- Clinical phenotyping in sarcoidosis using cluster analysis.Respiratory research · 2022Article
- Sarcoidosis-Related Cardiomyopathy: Current Knowledge, Challenges, and Future Perspectives State-of-the-Art Review.Journal of cardiac failure · 2022Review
- Epigenetics and sarcoidosis.European respiratory review : an official journal of the European Respiratory Society · 2021Review
- Serum B cell activating factor (BAFF) and sarcoidosis activity.Archives of rheumatology · 2021Article
- Inflammatory Pathways in Sarcoidosis.Advances in experimental medicine and biology · 2021Article
- Osteopontin Gene Polymorphisms rs1126616 C>T and rs1126772 A>G are Associated with Atopic Dermatitis in Polish Population.The application of clinical genetics · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
Abstract
backgroundIdentification of serum proteins that track with disease course in sarcoidosis may have clinical and pathologic importance. We previously identified up-regulated transcripts for interferon-inducible chemokines CXCL9, and CXCL10, in blood of sarcoidosis patients compared to controls. The objective of this study was to determine whether proteins encoded by these transcripts were elevated in serum and identified patients with remitting vs. chronic progressive sarcoidosis longitudinally.
methodsSerum levels of CXCL9, CXCL10, and proteins associated with inflammation and/or disease activity (sIL2R, ACE, ESR and CRP) were measured in a prospective cohort of sarcoidosis subjects and controls. Comparisons were made between groups and clinical course using pulmonary function measures and a severity score developed by Wasfi et al.
resultsIn a cross-sectional analysis of 36 non-immunosuppressed sarcoidosis subjects, serum CXCL9, CXCL10, and sIL2R were significantly elevated compared to 46 controls (p < 0.0001). CXCL9 and CXCL10 were strongly inter-correlated (p = 0.0009). CXCL10 and CXCL9 were inversely correlated with FVC% predicted and DLCO% predicted, respectively. CXCL10 and CXCL9 significantly correlated with sarcoidosis severity score. sIL2R, ESR, CRP, and ACE serum levels did not correlate with pulmonary function measures or severity score. In the longitudinal analysis of 26 subjects, changes in serum CXCL10 level over time corresponded with progression versus remission of disease.
conclusionsInterferon-γ-inducible chemokines, CXCL9 and CXCL10, are elevated in sarcoidosis and inter-correlated with each other. Chemokine levels correlated with measures of disease severity. Serial measurements of CXCL10 corresponded to clinical course.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.